DexCom (DXCM) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Dexcom Inc (DXCM) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Dexcom is a medical device company that makes continuous glucose monitoring systems, and the story here is a high-quality diabetes tech business still growing well, though investors are watching whether U.S. growth is cooling. > **📍 Basic Profile** > > Market Cap **$28.45 billion** · Health Care / Medical Devices · NASDAQ NMS - GLOBAL MARKET · Price **$73.74** > **⚡ 3 Things You Should Know** > > 1. 💰 High-quality profit engine: Dexcom is not just growing—it’s already meaningfully profitable, with **63.43% gross margin**, **19.31% net margin**, and **33.83% ROE**. In other words, this is a growth company that has already crossed into real earnings power. > > 2. 📈 Growth is still solid, but the mix matters: Q1 2026 revenue grew **15%**, with **international up 26%** while U.S. growth was slower. What’s interesting is that the company still has expansion runway, but the market will care a lot about whether overseas momentum can offset a maturing home market. > > 3. 🏷️ Valuation is no longer bargain-basement, but not extreme either: At about **30.5x TTM PE** and trading around the upper half of its 52-week range, the stock is priced for continued execution. Basically, this means investors are willing to pay up for quality, but probably not forgive a major slowdown. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Strong💪 | Net margin 19.31%, strong for a medical device growth company | > | Growth Rate | Steady📈 | Revenue growth 15% in latest quarter; 3Y revenue CAGR 17.01% | > | Financial Health | Healthy💚 | Debt-to-equity 47.15%, current ratio 1.95, interest coverage 978 | > | Valuation | Fair | PE 30.49x, reflecting quality growth rather than deep value | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Dexcom sells continuous glucose monitoring (CGM) devices and related diabetes management technology to patients, providers, and healthcare systems, making money from recurring sensor usage and hardware adoption. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | CGM products and sensors | [Data unavailable] | ↑ | Core business, likely driven by recurring sensor demand | | International expansion | [Data unavailable] | ↑ | Fast-growing and increasingly important growth lever | | U.S. market | [Data unavailable] | → | Still large, but recent commentary suggests moderation versus international | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 63.43% | Top-tier | Shows strong pricing power and attractive unit economics | | Net Margin | 19.31% | Above Average | Means Dexcom converts a good share of revenue into bottom-line profit | | ROE | 33.83% | Excellent>20% | Indicates very strong shareholder capital efficiency | --- #### 📈 How's the Growth? **Growth Assessment:** Steady Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | 15.0% | [Data unavailable] | Stable | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > Worth noting, this looks like fairly healthy growth rather than something artificially inflated. Recent reports point to **international demand, product momentum, and coverage expansion** as key drivers. The one thing to watch is that U.S. growth appears to be moderating, so future upside may depend more on execution outside the U.S. and continued category expansion. --- #### 💰 Financial Health Check **One Sentence:** Dexcom’s balance sheet looks like someone with a strong paycheck, manageable debt, and plenty of room to cover bills—comfortable rather than stretched. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 47.15% | <60% safe | ✅Safe | | Current Ratio | 1.95 | >1.5 healthy | ✅Safe | | Cash Flow | Positive (cash flow/share TTM $1.28) | >0 | ✅Positive | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $54.11 - 52-Week High: $89.98 - Current: $73.74, **in the upper-middle of the range** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | ●(54.7% position) | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 30.49x | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE 30.49x | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the market is betting Dexcom can remain a durable double-digit grower while keeping margins strong. After the recent Investor Day and the new **$1 billion buyback**, investors also seem to be pricing in confidence that management can balance growth and shareholder returns. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-05 | Investor Day outlined longer-term growth/profitability targets and a new **$1.0B buyback** | Positive — improved sentiment and signals management confidence | | 2026-04 | Q1 2026 revenue reached **$1.19B**, up **15% YoY** | Positive — shows growth remains healthy despite U.S. moderation | | 2026-04 | Q1 EPS of **$0.56** beat consensus by **17.0%** | Positive — suggests execution was better than analysts expected | | 2026-05 | Commentary highlighted strong earnings quality | Positive — reinforces that profits appear supported by underlying operations | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 63.43% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 19.31% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 33.83% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | 15.0% (latest quarter) | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↑ (3Y EPS growth 37.23%) | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2026-03-31 | $0.48 | $0.56 | +17.0% Beat 😀 | | 2025-12-31 | $0.66 | $0.45 | -32.1% Miss 😟 | | 2025-09-30 | $0.58 | $0.61 | +5.3% Beat 😀 | | 2025-06-30 | $0.45 | $0.48 | +6.8% Beat 😀 | **Earnings Trend Interpretation:** Dexcom’s earnings track record is mostly solid, but not perfectly smooth. Three beats out of four quarters is good, but that large Q4 2025 miss is a reminder that expectations can get ahead of results. In other words, this is an execution story, not a “set it and forget it” stock. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 32 firms | 86.5% | | Hold | 4 firms | 10.8% | | Sell | 1 firm | 2.7% | **Target Price:** [Data unavailable] **vs Current Price:** [Data unavailable] **Insider Activity:** Net selling in the past 3 months based on the provided filings > Worth noting, a chunk of the recent insider activity includes **transaction code F**, which often relates to tax withholding rather than a pure discretionary sale. Still, there were also open-market sales, so this is mildly cautious rather than a major red flag. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **U.S. Growth Moderation:** Recent commentary points to slower U.S. growth → If this continues, it could lead to lower overall growth and pressure on the premium valuation 2. **Expectation Risk:** The stock trades at a quality-growth multiple and analysts are overwhelmingly bullish → If execution slips, the downside reaction could be sharp 3. **Concentration Risk:** Dexcom is heavily tied to the CGM category → If competition intensifies, reimbursement changes, or adoption slows, it could hit both margins and growth --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Dexcom is a leading diabetes technology company built around continuous glucose monitoring, with a business model that benefits from recurring usage and expanding adoption. > > **Key strength:** The biggest plus is that it combines **real profitability, strong returns on capital, and still-solid double-digit growth**, which is a rare mix. > > **Key risk:** The main concern is that the stock still needs continued execution—especially as U.S. growth cools—because at around **30x earnings**, this is not a stock the market will treat patiently if growth disappoints. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis